Disease management
The company's Dexcom Smart Basal will provide patients with a user-friendly option.
The feature uses machine learning and heart sensor data to flag signs of hypertension and will roll out to Watch Series 9, 10 and 11 as well as Ultra 2 and 3 by month’s end.
The company will use the funds to improve its value-based care model, including its AI and analytics tools, and expand its partnerships and services.
Also, Indian e-pharmacy PlatinumRx has raised $6 million in Series A funding for its expansion.
The company will use the funding to further develop its SmartShunt System, aimed at reducing shunt failures and improving care for patients with hydrocephalus.
ArteraAI Prostate uses digital pathology images from a patient’s biopsy to predict potential long-term outcomes of their prostate cancer.
The companies will develop AI models trained on real-world data to help identify and diagnose patients with paroxysmal nocturnal hemoglobinuria.
The alliance aims to benefit patients with chronic conditions and allow real-time interoperability among healthcare providers, pharmacies and payers.
The company will use the funds to expand its technology offerings and nationwide partnerships.
Data from Dexcom CGMs will be integrated into FriskaAi and will be monitored by AI-powered algorithms that alert patients when action is advised.